FDA Staff Has Concerns Over Endo Testosterone Replacement
Endo's testosterone replacement therapy Aveed, an intramuscular injection, has been rejected by the FDA twice so far, in 2008 and 2009, over similar safety issues.
At issue is the risk of severe adverse reactions after injection. Patients could experience a potentially fatal...
To view the full article, register now.